BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Strosberg J, Kvols L. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol 2010; 16(24): 2963-2970 [PMID: 20572298 DOI: 10.3748/wjg.v16.i24.2963]
URL: https://www.wjgnet.com/1007-9327/full/v16/i24/2963.htm
Number Citing Articles
1
Alessandro Zerbi, Vanessa Capitanio, Letizia Boninsegna, Gianfranco Delle Fave, Claudio Pasquali, Guido Rindi, Davide Campana, Massimo Falconi. Treatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre studyHPB 2013; 15(12): 935 doi: 10.1111/hpb.12065
2
Jonathan R. Strosberg. Systemic Treatment of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS): Cuirrent Approaches and Future OptionsEndocrine Practice 2014; 20(2): 167 doi: 10.4158/EP13262.RA
3
Akshat Saxena, Terence C. Chua, Marlon Perera, Francis Chu, David L. Morris. Surgical resection of hepatic metastases from neuroendocrine neoplasms: A systematic reviewSurgical Oncology 2012; 21(3): e131 doi: 10.1016/j.suronc.2012.05.001
4
Daniel Putzer, Alexander Kroiss, Dietmar Waitz, Michael Gabriel, Tatjana Traub-Weidinger, Christian Uprimny, Elisabeth von Guggenberg, Clemens Decristoforo, Boris Warwitz, Gerlig Widmann, Irene Johanna Virgolini. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotideEuropean Journal of Nuclear Medicine and Molecular Imaging 2013; 40(3): 364 doi: 10.1007/s00259-012-2286-6
5
Mauro Cives, Jonathan Strosberg. The Expanding Role of Somatostatin Analogs in Gastroenteropancreatic and Lung Neuroendocrine TumorsDrugs 2015; 75(8): 847 doi: 10.1007/s40265-015-0397-7
6
Ágota Petrányi, György Bodoky. Drugs for the treatment of neuroendocrine tumoursOrvosi Hetilap 2011; 152(10): 379 doi: 10.1556/OH.2011.29060
7
Chanjuan Shi, David S. Klimstra. Pancreatic neuroendocrine tumors: Pathologic and molecular characteristicsSeminars in Diagnostic Pathology 2014; 31(6): 498 doi: 10.1053/j.semdp.2014.08.008
8
Kjell E Öberg. Management of neuroendocrine tumors: current and future therapiesExpert Review of Endocrinology & Metabolism 2011; 6(1): 49 doi: 10.1586/eem.10.81
9
Alejandro Garcia-Alvarez, Jorge Hernando Cubero, Jaume Capdevila. Drug Development in Neuroendocrine Tumors: What Is on the Horizon?Current Treatment Options in Oncology 2021; 22(5) doi: 10.1007/s11864-021-00834-3
10
Marc Remke, Esther Hering, Nicolas U. Gerber, Marcel Kool, Dominik Sturm, Christian H. Rickert, Joachim Gerß, Stefan Schulz, Thomas Hielscher, Martin Hasselblatt, Astrid Jeibmann, Volkmar Hans, Vijay Ramaswamy, Michael D. Taylor, Torsten Pietsch, Stefan Rutkowski, Andrey Korshunov, Carmelia-Maria Monoranu, Michael C. Frühwald. Somatostatin receptor subtype 2 (sst2) is a potential prognostic marker and a therapeutic target in medulloblastomaChild's Nervous System 2013; 29(8): 1253 doi: 10.1007/s00381-013-2142-4
11
Annemiek Walenkamp, Guillermo Crespo, Felipe Fierro Maya, Reidar Fossmark, Peter Igaz, Anja Rinke, Gianluca Tamagno, Giovanni Vitale, Kjell Öberg, Tim Meyer. Hallmarks of gastrointestinal neuroendocrine tumours: implications for treatmentEndocrine-Related Cancer 2014; 21(6): R445 doi: 10.1530/ERC-14-0106
12
Laura Lattanzio, Federica Tonissi, Martino Monteverde, Gerard Milano, Marco C. Merlano, Cristiana Lo Nigro. Differential molecular mechanism of docetaxel–octreotide combined treatment according to the docetaxel-resistance status in PC3 prostate cancer cellsAnti-Cancer Drugs 2013; 24(2): 120 doi: 10.1097/CAD.0b013e328358d1dc
13
Elizabeta Popa, Felice Schnoll-Sussman, Arun Jesudian, Govind Nandakumar, Manish A. Shah. Textbook of Uncommon Cancer2012; : 389 doi: 10.1002/9781118464557.ch28
14
C.J. Auernhammer, C. Spitzweg, V. Heinemann, B. Göke. Medikamentöse Therapie bei metastasierten neuroendokrinen Tumoren des gastroenteropankreatischen SystemsWiener klinisches Magazin 2013; 16(3): 16 doi: 10.1007/s00740-013-0114-7
15
Alan Meeker, Christopher Heaphy. Gastroenteropancreatic endocrine tumorsMolecular and Cellular Endocrinology 2014; 386(1-2): 101 doi: 10.1016/j.mce.2013.07.015
16
L. E. Gurevich, N. A. Korsakova, I. A. Voronkova, V. E. Ashevskaya , A. G. Titov, L. M. Kogoniya, A. V. Egorov, T. A. Britvin, I. A. Vasil'ev. IMMUNOHISTOCHEMICAL DETERMINATION OF EXPRESSION OF SOMATOSTATIN RECEPTORS TYPES 1, 2A, 3 AND 5 IN NEUROENDOCRINE TUMORS OF VARIOUS LOCALIZATION AND GRADEAlmanac of Clinical Medicine 2016; 44(4): 378 doi: 10.18786/2072-0505-2016-44-4-378-390
17
Daphne Adelman, Xuan-Mai Truong Thanh, Marion Feuilly, Aude Houchard, David Cella. Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO)Advances in Therapy 2020; 37(4): 1608 doi: 10.1007/s12325-020-01255-8
18
Ryo Shimoyama, Susumu Hijioka, Nobumasa Mizuno, Gakuto Ogawa, Tomoko Kataoka, Hiroshi Katayama, Nozomu Machida, Yoshitaka Honma, Narikazu Boku, Tetsuya Hamaguchi, Haruhiko Fukuda, Masanori Terashima, Yukihide Kanemitsu, Junji Furuse. Study protocol for a multi-institutional randomized phase III study comparing combined everolimus plus lanreotide therapy and everolimus monotherapy in patients with unresectable or recurrent gastroenteropancreatic neuroendocrine tumors; Japan Clinical Oncology Group Study JCOG1901 (STARTER-NET study)Pancreatology 2020; 20(6): 1183 doi: 10.1016/j.pan.2020.07.010
19
Maridi Aerts, Hendrik Reynaert. Disease Control on Lanreotide Autogel® 120 mg in a Patient with Metastatic Gastrinoma: A Case ReportCase Reports in Gastroenterology 2017; 11(3): 616 doi: 10.1159/000485025
20
Dan Granberg. Advances in Pulmonary Neuroendocrine Tumor Management2013; : 36 doi: 10.2217/ebo.12.79
21
Tetsuhide Ito, Yoshitaka Honma, Susumu Hijioka, Atsushi Kudo, Akira Fukutomi, Akira Nozaki, Yasutoshi Kimura, Fuyuhiko Motoi, Hiroyuki Isayama, Izumi Komoto, Seiichi Hisamatsu, Akihiro Nakajima, Akira Shimatsu. Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumorsInvestigational New Drugs 2017; 35(4): 499 doi: 10.1007/s10637-017-0466-8
22
Jonathan Strosberg. Neuroendocrine tumours of the small intestineBest Practice & Research Clinical Gastroenterology 2012; 26(6): 755 doi: 10.1016/j.bpg.2012.12.002
23
C.J. Auernhammer, C. Spitzweg, V. Heinemann, B. Göke. Medikamentöse Therapie bei metastasierten neuroendokrinen Tumoren des gastroenteropankreatischen SystemsDer Internist 2012; 53(2): 167 doi: 10.1007/s00108-011-2919-z
24
Thomas Walter, Hedia Brixi-Benmansour, Catherine Lombard-Bohas, Guillaume Cadiot. New treatment strategies in advanced neuroendocrine tumoursDigestive and Liver Disease 2012; 44(2): 95 doi: 10.1016/j.dld.2011.08.022
25
A. Amador Cano, F. García, A. Espinoza, N. Bezies, E. Herrera, J. De Leija Portilla. Nonfunctional neuroendocrine tumor of the pancreas: Case report and review of the literatureInternational Journal of Surgery Case Reports 2013; 4(2): 225 doi: 10.1016/j.ijscr.2012.10.018
26
Tak Geun Oh, Moon Jae Chung, Jeong Yeop Park, Seung Min Bang, Seung Woo Park, Jae Bok Chung, Si Young Song. Prognostic Factors and Characteristics of Pancreatic Neuroendocrine Tumors: Single Center ExperienceYonsei Medical Journal 2012; 53(5): 944 doi: 10.3349/ymj.2012.53.5.944
27
Hisato Igarashi, Masayuki Hijioka, Lingaku Lee, Tetsuhide Ito. Biotherapy of pancreatic neuroendocrine tumors using somatostatin analogsJournal of Hepato-Biliary-Pancreatic Sciences 2015; 22(8): 618 doi: 10.1002/jhbp.227
28
Sirine Jaber, Ivan Iliev, Tsvetelina Angelova, Veronica Nemska, Inna Sulikovska, Emilia Naydenova, Nelly Georgieva, Ivan Givechev, Ivo Grabchev, Dancho Danalev. Synthesis, Antitumor and Antibacterial Studies of New Shortened Analogues of (KLAKLAK)2-NH2 and Their Conjugates Containing Unnatural Amino AcidsMolecules 2021; 26(4): 898 doi: 10.3390/molecules26040898
29
Jonathan Strosberg. The American Cancer Society's Oncology in Practice2018; : 552 doi: 10.1002/9781118592168.ch39
30
Jonathan Strosberg. Neuroendocrine Tumours2015; : 523 doi: 10.1007/978-3-662-45215-8_30
31
Kathleen K. Christians, George Younan, Ben George, Susan Tsai, Douglas B. Evans. Difficult Decisions in Endocrine SurgeryDifficult Decisions in Surgery: An Evidence-Based Approach 2018; : 441 doi: 10.1007/978-3-319-92860-9_36
32
Maxime Palazzo, Catherine Lombard-Bohas, Guillaume Cadiot, Tamara Matysiak-Budnik, Vinciane Rebours, Marie-Pierre Vullierme, Anne Couvelard, Olivia Hentic, Philippe Ruszniewski. Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumorsEuropean Journal of Gastroenterology & Hepatology 2013; 25(2): 232 doi: 10.1097/MEG.0b013e328359d1a6
33
Christos Toumpanakis, Martyn E. Caplin. Update on the Role of Somatostatin Analogs for the Treatment of Patients With Gastroenteropancreatic Neuroendocrine TumorsSeminars in Oncology 2013; 40(1): 56 doi: 10.1053/j.seminoncol.2012.11.006
34
Emilia Naydenova, Diana Wesselinova, Svetlana Staykova, Dancho Danalev, Tatyana Dzimbova. Synthesis, in vitro biological activity and docking of new analogs of BIM-23052 containing unnatural amino acidsAmino Acids 2019; 51(9): 1247 doi: 10.1007/s00726-019-02758-7
35
Svetlana Ts. Staykova, Diana W. Wesselinova, Lyubomir T. Vezenkov, Emilia D. Naydenova. Synthesis and in vitro antitumor activity of new octapeptide analogs of somatostatin containing unnatural amino acidsAmino Acids 2015; 47(5): 1007 doi: 10.1007/s00726-015-1929-x
36
Elisabeth Fabian, Bernhard Haas, Patrizia Kump, Rainer Lipp, Peter Kornprat, Andre Lutfi, Emina Talakic, Michael Fuchsjäger, Walter Spindelboeck, Carolin Lackner, Gernot Zollner, Guenter J. Krejs. Clinical–Pathological Conference Series from the Medical University of GrazWiener klinische Wochenschrift 2016; 128(7-8): 277 doi: 10.1007/s00508-016-0965-1
37
M. Albertelli, E. Nazzari, S. Sciallero, F. Grillo, S. Morbelli, F. De Cian, G. Cittadini, E. Ambrosetti, A. Ciarmiello, D. Ferone. Anti-tumoral effects of somatostatin analogs: a lesson from the CLARINET studyJournal of Endocrinological Investigation 2017; 40(11): 1265 doi: 10.1007/s40618-017-0692-0
38
Aleksandra Marciniak, Justyna Brasuń. Somatostatin analogues labeled with copper radioisotopes: current statusJournal of Radioanalytical and Nuclear Chemistry 2017; 313(2): 279 doi: 10.1007/s10967-017-5323-x
39
Lucas Sidéris, Pierre Dubé, Anja Rinke. Antitumor Effects of Somatostatin Analogs in Neuroendocrine TumorsThe Oncologist 2012; 17(6): 747 doi: 10.1634/theoncologist.2011-0458
40
Anna J Sharp, Aimee R Hayes, Ashley Grossman. High-dose Somatostatin Analogues for Progressive Neuroendocrine TumoursEuropean Endocrinology 2020; 16(2): 93 doi: 10.17925/EE.2020.16.2.93
41
Tetsuhide Ito, Hisato Igarashi, Hirotsugu Uehara, Robert T Jensen. Pharmacotherapy of Zollinger–Ellison syndromeExpert Opinion on Pharmacotherapy 2013; 14(3): 307 doi: 10.1517/14656566.2013.767332
42
E. Wynendaele, E. Pauwels, C. Van de Wiele, C. Burvenich, B. De Spiegeleer. The potential role of quorum-sensing peptides in oncologyMedical Hypotheses 2012; 78(6): 814 doi: 10.1016/j.mehy.2012.03.018
43
A. Viúdez, A. De Jesus-Acosta, F.L. Carvalho, R. Vera, S. Martín-Algarra, N. Ramírez. Pancreatic neuroendocrine tumors: Challenges in an underestimated diseaseCritical Reviews in Oncology/Hematology 2016; 101: 193 doi: 10.1016/j.critrevonc.2016.03.013
44
Gary B. Deutsch, Ji Hey Lee, Anton J. Bilchik. Long-Term Survival with Long-Acting Somatostatin Analogues Plus Aggressive Cytoreductive Surgery in Patients with Metastatic Neuroendocrine CarcinomaJournal of the American College of Surgeons 2015; 221(1): 26 doi: 10.1016/j.jamcollsurg.2015.03.055
45
Rosa Maria Paragliola, Roberto Salvatori. Novel Somatostatin Receptor Ligands Therapies for AcromegalyFrontiers in Endocrinology 2018; 9 doi: 10.3389/fendo.2018.00078
46
Frédérique Maire, Philippe Ruszniewski. Somatostatin Analogues2015; : 189 doi: 10.1002/9781119031659.ch17
47
Jonathan R. Strosberg, Asima Cheema, Larry K. Kvols. A Review of Systemic and Liver-Directed Therapies for Metastatic Neuroendocrine Tumors of the Gastroenteropancreatic TractCancer Control 2011; 18(2): 127 doi: 10.1177/107327481101800207
48
Kyung Won Kim, Katherine M. Krajewski, Mizuki Nishino, Jyothi P. Jagannathan, Atul B. Shinagare, Sree Harsha Tirumani, Nikhil H. Ramaiya. Update on the Management of Gastroenteropancreatic Neuroendocrine Tumors With Emphasis on the Role of ImagingAmerican Journal of Roentgenology 2013; 201(4): 811 doi: 10.2214/AJR.12.10240
49
Tetsuhide Ito, Hisato Igarashi, Robert T. Jensen. Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advancesJournal of Gastroenterology 2012; 47(9): 941 doi: 10.1007/s00535-012-0642-8
50
Su-Chen Li, Cécile Martijn, Tao Cui, Ahmed Essaghir, Raúl M. Luque, Jean-Baptiste Demoulin, Justo P. Castaño, Kjell Öberg, Valeria Giandomenico, Miguel López. The Somatostatin Analogue Octreotide Inhibits Growth of Small Intestine Neuroendocrine Tumour CellsPLoS ONE 2012; 7(10): e48411 doi: 10.1371/journal.pone.0048411
51
Heloisa Prado Soares, Jonathan Strosberg. Neuroendocrine Tumors: Review of Pathology, Molecular and Therapeutic Advances2016; : 505 doi: 10.1007/978-1-4939-3426-3_28
52
Jean Claude Reubi, Agnes Schonbrunn. Illuminating somatostatin analog action at neuroendocrine tumor receptorsTrends in Pharmacological Sciences 2013; 34(12): 676 doi: 10.1016/j.tips.2013.10.001
53
Jonathan Strosberg. Evolving Treatment Strategies for Management of Carcinoid TumorsCurrent Treatment Options in Oncology 2013; 14(3): 374 doi: 10.1007/s11864-013-0246-4
54
Theresa R. Harring, N. Thao N. Nguyen, John A. Goss, Christine A. O'Mahony. Treatment of Liver Metastases in Patients with Neuroendocrine Tumors: A Comprehensive ReviewInternational Journal of Hepatology 2011; 2011: 1 doi: 10.4061/2011/154541
55
Esther Una Cidon. New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the futureWorld Journal of Gastrointestinal Oncology 2017; 9(1): 4-20 doi: 10.4251/wjgo.v9.i1.4
56
Aura D. Herrera-Martínez, Manuel D. Gahete, Sergio Pedraza-Arevalo, Rafael Sánchez-Sánchez, Rosa Ortega-Salas, Raquel Serrano-Blanch, Raúl M. Luque, María A. Gálvez-Moreno, Justo P. Castaño. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumorsEndocrine 2018; 59(2): 426 doi: 10.1007/s12020-017-1482-3
57
Giuseppe Nigri, Niccolò Petrucciani, Tarek Debs, Livia Maria Mangogna, Anna Crovetto, Giovanni Moschetta, Raffaello Persechino, Paolo Aurello, Giovanni Ramacciato. Treatment options for PNET liver metastases: a systematic reviewWorld Journal of Surgical Oncology 2018; 16(1) doi: 10.1186/s12957-018-1446-y
58
Tetsuhide Ito, Hisato Igarashi, Robert T. Jensen. Zollinger–Ellison syndromeCurrent Opinion in Gastroenterology 2013; 29(6): 650 doi: 10.1097/MOG.0b013e328365efb1
59
Daniela Molè, Erica Gentilin, Alejandro Ibañez-Costa, Teresa Gagliano, Manuel D. Gahete, Federico Tagliati, Roberta Rossi, Maria Rosa Pelizzo, Giancarlo Pansini, Raúl M. Luque, Justo P. Castaño, Ettore degli Uberti, Maria Chiara Zatelli. The expression of the truncated isoform of somatostatin receptor subtype 5 associates with aggressiveness in medullary thyroid carcinoma cellsEndocrine 2015; 50(2): 442 doi: 10.1007/s12020-015-0594-x
60
Catherine T. Anthony, Juan G. Bastidas, Jessica L. Thomson, John Lyons, James M. Lewis, Joshua E. Schwimer, Peter Casey, Jennifer Abadie, Daniel J. Frey, Yi-Zarn Wang, J. Philip Boudreaux, Eugene A. Woltering. A Study of Pipeline Drugs in Neuroendocrine TumorsJournal of Gastrointestinal Cancer 2012; 43(2): 296 doi: 10.1007/s12029-011-9286-9
61
Aleksandra Marciniak, Marek Cebrat, Żaneta Czyżnikowska, Justyna Brasuń. Novel short-chain analogues of somatostatin as ligands for Cu(II) ions. Role of the metal ion binding on the spatial structure of the ligandJournal of Inorganic Biochemistry 2012; 117: 10 doi: 10.1016/j.jinorgbio.2012.08.023
62
Robert T. Jensen. Yamada' s Textbook of Gastroenterology2015; : 1078 doi: 10.1002/9781118512074.ch57
63
Tetsuhide Ito, Nao Fujimori, Yoshitaka Honma, Atsushi Kudo, Susumu Hijioka, Shinji Katsushima, Yasutoshi Kimura, Akira Fukutomi, Seiichi Hisamatsu, Akihiro Nakajima, Akira Shimatsu. Long‐term safety and efficacy of lanreotide autogel in Japanese patients with neuroendocrine tumors: Final results of a phase II open‐label extension studyAsia-Pacific Journal of Clinical Oncology 2021; 17(5) doi: 10.1111/ajco.13371
64
Michaela S. Banck, Andreas S. Beutler. Advances in small bowel neuroendocrine neoplasiaCurrent Opinion in Gastroenterology 2014; 30(2): 163 doi: 10.1097/MOG.0000000000000043
65
Sara Massironi, Dario Conte, Roberta Elisa Rossi. Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedulesScandinavian Journal of Gastroenterology 2016; 51(5): 513 doi: 10.3109/00365521.2015.1115117
66
Susumu Hijioka, Chigusa Morizane, Masafumi Ikeda, Hiroshi Ishii, Takuji Okusaka, Junji Furuse. Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectivesJapanese Journal of Clinical Oncology 2021; 51(8): 1185 doi: 10.1093/jjco/hyab076
67
Venkata K. Pokuri, Mei Ka Fong, Renuka Iyer. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine TumorsCurrent Oncology Reports 2016; 18(1) doi: 10.1007/s11912-015-0492-7
68
Stefano Cappato, Federica Brena, Michela Squadroni, Rosalba Barile, Davide Piccinali, Annalisa Mancin, Giorgio Quartierini, Orlando Goletti, Giordano Beretta. Clinical Applications of Nuclear Medicine Targeted Therapy2018; : 153 doi: 10.1007/978-3-319-63067-0_14
69
MUHITTIN ERTILAV, ENDER HUR, DEVRIM BOZKURT, SAVAS SIPAHI, OZGE TIMUR, BANU SARSIK, FEHMI AKCICEK, SONER DUMAN. Octreotide lessens peritoneal injury in experimental encapsulated peritoneal sclerosis modelNephrology 2011; 16(6): 552 doi: 10.1111/j.1440-1797.2011.01460.x
70
Emilio Bajetta, Laura Catena, Nicola Fazio, Sara Pusceddu, Pamela Biondani, Giusi Blanco, Sergio Ricci, Michele Aieta, Francesca Pucci, Monica Valente, Nadia Bianco, Chiara Maria Mauri, Francesca Spada. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: An ITMO group studyCancer 2014; 120(16): 2457 doi: 10.1002/cncr.28726
71
Marta Martín-Richard, Bartomeu Massutí, Eva Pineda, Vicente Alonso, Maribel Marmol, Daniel Castellano, Emilio Fonseca, Antonio Galán, Marta Llanos, Maria Angeles Sala, Carlos Pericay, Fernando Rivera, Javier Sastre, Ángel Segura, Maria Quindós, Pascal Maisonobe. Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II studyBMC Cancer 2013; 13(1) doi: 10.1186/1471-2407-13-427